Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)

NCT07405190 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07405190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07405190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2026
Completion date
March 1, 2029
Enrollment
46 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

genomic alterations, lung cancer (non-small cell), lung cancer (nsclc), lung cancer - non small cell, lung cancer non small cell, lung cancer non-small cell cancer (nsclc)